All In Biotech

Drug Trial Radar · NCT05345691

Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis

A Randomized, Double-Blind, Multicenter, Parallel-Arm Phase 3 Study to Compare the Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis

Last checked: Nov 20, 2026Latest source record: Sep 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 479 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

479

Actual

Start

May 24, 2022

Primary completion

Jun 12, 2024

Study completion Jun 12, 2024

Sponsor

Lead sponsor
Biocon Biologics UK LtdIndustry
Sponsor type
Industry
First posted
Apr 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 55 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, multicenter, parallel-arm, Phase 3 study to compare the efficacy, PK (Pharmacokinetic), PD (Pharmacodynamic), safety, and immunogenicity of Bmab 1000 and Prolia® in postmenopausal women with osteoporosis

Conditions

  • Postmenopausal Women With Osteoporosis

Interventions

  • Bmab 1000Biological

    60 mg administered as a single SC (subcutaneous) injection once every 6 months.

  • Prolia®Biological

    60 mg administered as a single SC injection once every 6 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Change in Lumbar Spine BMD (Bone Mineral Density)Time frame: Baseline and Week 52

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PPD Global Ltd, Granta Park, Great Abington,

    Cambridge, UK, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.